Simulations Plus Inc
Suletud
SektorTervishoid
16.57 3.24
Ülevaade
Aktsiahinna muutus
24h
Min
16.06
Max
17.03
Sissetulek | 3.9M 4.5M |
|---|---|
Müük | 5.9M 24M |
Aktsiakasum | 0.35 |
Kasumimarginaal | 18.669 |
Töötajad | 212 |
EBITDA | 4.9M 7.2M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | -4.59% downside |
Järgmine tulemuste avaldamine | 13. juuli 2026 |
|---|
Turukapital | 107M 358M |
|---|---|
Eelmine avamishind | 13.33 |
Eelmine sulgemishind | 16.57 |
Simulations Plus Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Simulations Plus Inc Prognoos
Hinnasiht
By TipRanks
-4.59% langus
12 kuu keskmine prognoos
Keskmine 16 USD -4.59%
Kõrge 16 USD
Madal 16 USD
Põhineb 3 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Simulations Plus Inc
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
